Latest News in the pharma Industry

Research & Development

NovaBiotics' cysteamine (Nylexa) breaks resistance in MDR bacteria

NovaBiotics' cysteamine (Nylexa) breaks resistance in MDR bacteria

19 Jun 2016

Results show that cysteamine reverses resistance to clinically important antibiotic classes such as aminoglycosides, fluoroquinolones, macrolides, folate pathway inhibitors and beta-lactams.

Read more 
ARIAD completes strategic review and announces plans for growth

ARIAD completes strategic review and announces plans for growth

19 Jun 2016

Key outcome of the strategic review is a commitment to commercializing brigatinib in the US, subject to approval by the FDA.

Read more 
Breakthrough combination for patients with skin cancer receives fast-tracked ‘yes’ from NICE

Breakthrough combination for patients with skin cancer receives fast-tracked ‘yes’ from NICE

17 Jun 2016

This represents one of the fastest ever approvals by NICE – UK patients will be the first to benefit across Europe.

Read more 
NICE denies NHS patients access to Vertex's Orkambi

NICE denies NHS patients access to Vertex's Orkambi

17 Jun 2016

“As a result of applying the wrong appraisal process, approximately 2,700 people in England who could benefit from Orkambi are being forced to continue waiting for access.”

Read more 
Zika vaccine race overlooks need for global strategy to combat mosquito-borne diseases

Zika vaccine race overlooks need for global strategy to combat mosquito-borne diseases

16 Jun 2016

Vast majority of Zika vaccine products are currently in early preclinical trials, indicating that it will take many years until one of them receives market approval, says GlobalData.

Read more 
Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment

Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment

15 Jun 2016

KAF156 belongs to a novel class of antimalarials that act against both the blood and liver stages of the parasite's lifecycle.

Read more 
ASCO 2016: Roche’s latest Tecentriq results underline potential to dominate bladder cancer market

ASCO 2016: Roche’s latest Tecentriq results underline potential to dominate bladder cancer market

14 Jun 2016

The launch of Roche’s recently-approved PD-1 immune checkpoint inhibitor Tecentriq will usher in a dramatic change in the treatment paradigm of metastatic bladder cancer, says GlbalData.

Read more 
Pharmaceutical companies increasingly looking to innovate high-risk, first-in-class products

Pharmaceutical companies increasingly looking to innovate high-risk, first-in-class products

14 Jun 2016

'Imperatives for pharmaceutical companies include reducing product development costs, maximizing the annual product revenue, and optimizing the life cycle of a drug,' says GBI Research.

Read more 
Shire receives FDA Breakthrough Therapy Designation for SHP621 and SHP625, investigational products for rare GI conditions

Shire receives FDA Breakthrough Therapy Designation for SHP621 and SHP625, investigational products for rare GI conditions

13 Jun 2016

Read more 
True North’s TNT009 demonstrates high response rates and rapid onset of action in interim clinical data in patients with CAD

True North’s TNT009 demonstrates high response rates and rapid onset of action in interim clinical data in patients with CAD

13 Jun 2016

Data from ongoing Phase Ib clinical study presented at 21st Congress of the European Hematology Association in Copenhagen.

Read more 
New data from GAP landmark trial confirm Grazax prevents asthma symptoms in children

New data from GAP landmark trial confirm Grazax prevents asthma symptoms in children

13 Jun 2016

Patients showed modified immunological responses to grass pollen, indicating inhibition of disease progression.

Read more 
Merck to acquire Afferent Pharmaceuticals

Merck to acquire Afferent Pharmaceuticals

10 Jun 2016

Afferent Pharmaceuticals is a leader in the development of therapeutic candidates targeting the P2X3 receptor for the treatment of common, poorly-managed, neurogenic conditions.

Read more